Analyst Price Targets — AMRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 8:56 am | Ashwani Verma | UBS | $19.00 | $13.09 | TheFly | Amneal Pharmaceuticals initiated with a Buy at UBS |
| March 2, 2026 12:16 pm | Les Sulewski | Truist Financial | $17.00 | $13.45 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $17; Truist: 'Stock pullback a great entry point' |
| January 7, 2026 12:20 pm | — | Truist Financial | $15.00 | $12.99 | TheFly | Amneal Pharmaceuticals price target raised to $15 from $14 at Truist |
| December 8, 2025 9:24 pm | — | Barclays | $15.00 | $11.87 | TheFly | Amneal Pharmaceuticals initiated with an Overweight at Barclays |
| March 3, 2025 11:25 am | — | Barclays | $11.00 | $8.76 | TheFly | Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays |
| November 11, 2024 12:22 pm | David Amsellem | Piper Sandler | $11.00 | $8.29 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler |
| October 2, 2024 8:53 am | Les Sulewski | Truist Financial | $12.00 | $8.70 | TheFly | Amneal Pharmaceuticals price target raised to $12 from $10 at Truist |
| October 1, 2024 1:42 pm | Les Sulewski | Truist Financial | $10.00 | $8.70 | StreetInsider | Truist Securities Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX) |
| May 3, 2024 1:57 pm | Les Sulewski | Truist Financial | $9.00 | $6.76 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $9 at Truist Securities |
| March 21, 2024 8:43 am | David Amsellem | Piper Sandler | $8.00 | $6.29 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $8 at Piper Sandler |
Latest News for AMRX
On April 20, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 4.7%, bringing the current price to $13.26. The stock has traded within a 52-week range of $7.0
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function after switching to CREXONT® Patients switching to CREXONT® from RYTARY® gained 3.07 hours of additional daily “Good On” time and nearly doubled…
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it sees as an attractive entry point following a recent pullback. UBS said the stock's roughly 14% decline over the past two months presents an opportunity in the specialty pharmaceuticals group, where it views Amneal as having a stronger growth profile relative to…
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it...
BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, two widely prescribed respiratory products that were approved by the Food and Drug Administration (FDA) in 2025. These are the Company's first two metered-dose…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.